Ovagen — Research, Dosing & Price Guide

Ovagen is a hepatoprotective bioregulator peptide (Lys-Glu-Asp) developed by the Khavinson laboratory in Russia. It is designed to support liver function and regeneration by regulating gene expression in hepatocytes. As a short peptide bioregulator, it works at the epigenetic level to restore normal protein synthesis patterns in aged or damaged liver tissue.

Ovagen is a tripeptide that penetrates cell membranes and interacts with specific DNA sequences in hepatocyte nuclei, modulating gene expression related to liver regeneration, detoxification enzyme production, and hepatocyte proliferation. It regulates the synthesis of cytochrome P450 enzymes and glutathione-S-transferase, enhancing the liver's Phase I and Phase II detoxification capacity. The peptide also normalizes albumin and bilirubin production, supports bile acid metabolism, and reduces inflammatory cytokine expression in hepatic tissue. Like other Khavinson bioregulators, it works through epigenetic modulation rather than receptor binding.

• Khavinson et al. demonstrated Ovagen normalized hepatocyte function and protein synthesis in aged animal models
• Studies in Bulletin of Experimental Biology and Medicine showed the Lys-Glu-Asp tripeptide regulated gene expression in liver tissue cultures
• Research demonstrated improved liver function markers (ALT, AST, bilirubin) in rodent models of hepatotoxicity after Ovagen treatment
• Preclinical studies showed reduced fibrotic changes in liver tissue with chronic Ovagen administration

• Oral: 10–20 mg daily in capsule form for 10–30 days
• Repeat cycles every 3–6 months for ongoing hepatoprotection
• Can be taken with or without food
• For active liver support: 20 mg daily for 30 days
• For maintenance: 10 mg daily for 10–15 days every 4–6 months

Known Side Effects

• No significant adverse effects reported in published research
• Mild GI discomfort — infrequently reported, generally with oral dosing
• Theoretical risk of altered drug metabolism due to cytochrome P450 modulation
• Very limited safety data compared to pharmaceutical hepatoprotective agents

Safety Profile

Ovagen has a favorable safety profile based on Khavinson's bioregulator research spanning several decades. As a naturally occurring tripeptide sequence, it is expected to have low toxicity. No serious adverse events have been reported in published studies. However, clinical trial data in humans is very limited, and most evidence comes from preclinical and observational Russian studies. Individuals taking medications metabolized by cytochrome P450 enzymes should exercise caution, as Ovagen's effects on these enzymes could theoretically alter drug levels.

Days 1–10: No dramatic subjective effects expected. The peptide works at the epigenetic level, gradually modulating gene expression in hepatocytes. Days 10–30: Improved liver function markers may be measurable on bloodwork (ALT, AST trending toward optimal). Some users report improved digestion and reduced sensitivity to alcohol. Post-cycle: Benefits persist beyond the dosing period as the epigenetic changes in hepatocyte gene expression continue to influence protein synthesis for weeks to months.

Prices sourced from peptides.gg marketplace. Prices may vary.